Population pharmacokinetics and dose optimization of ceftazidime in critically ill children

Population pharmacokinetics and dose optimization of ceftazidime in critically ill children

ObjectiveThe aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.MethodsWe performed a prospective pharmacokinetic study on critically...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mengting Li, Liuliu Gao, Zuo Wang, Lingkong Zeng, Chen Chen, Jun Wang, Sichan Li, Maochang Liu, Yang Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Pharmacology
Subjects:	pediatric intensive care unit children ceftazidime population pharmacokinetics dose optimization
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1470350/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population Pharmacokinetics and Dosing Optimization of Norvancomycin for Chinese Patients with Community-Acquired Pneumonia
by: Li Y, et al.
Published: (2024-12-01)

Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection
by: Zhang R, et al.
Published: (2024-12-01)

Dosing Regimen Recommendations for Sirolimus in Adult Liver Transplant Recipients: Insights from a Population Pharmacokinetic Model
by: Mao J, et al.
Published: (2024-12-01)

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors
by: Takuya Azechi, et al.
Published: (2024-11-01)

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)

BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA
by: Alzbeta Zavrelova, et al.
Published: (2022-12-01)

Preservative-free electrospun nanofibrous inserts for sustained delivery of ceftazidime; design, characterization and pharmacokinetic investigation in rabbit's eye
by: Shiva Taghe, et al.
Published: (2024-12-01)

External validation of population pharmacokinetic models of gentamicin in paediatric population from preterm newborns to adolescents
by: Črček Mateja, et al.
Published: (2023-06-01)

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study
by: Yu CH, et al.
Published: (2024-12-01)

Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
by: Mi Zhou, et al.
Published: (2024-12-01)

External Validation of the Population Pharmacokinetic Models of Amisulpride and Remedial Strategies for Delayed or Missed Doses
by: Yan D, et al.
Published: (2024-12-01)

Ceftolozane-tazobactam, ceftazidime-avibactam and ceftazidime-avibactam plus aztreonam combination: Upcoming hope for hospital-acquired MDR/XDR Pseudomonas aeruginosa infections
by: Asmaa Elbrolosy, et al.
Published: (2024-05-01)

Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae
by: Yitan Li, et al.
Published: (2024-12-01)

The Use of Ceftazidime–Avibactam in a Pediatric Intensive Care Unit—An Observational Prospective Study
by: Raquel García Romero, et al.
Published: (2024-11-01)

The In Vitro Synergistic And Antibiofilm Activity Of Ceftazidime/Avibactam Against Achromobacter Species Isolated From Cystic Fibrosis Patients
by: EMEL MATARACI KARA, et al.
Published: (2024-12-01)

Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
by: Luca Mezzadri, et al.
Published: (2024-12-01)

Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area
by: Şevval Arduç Tok, et al.
Published: (2024-12-01)

Ceftazidime–avibactam for the Treatment of Intra-abdominal Sepsis and Urosepsis: A Retrospective Hospital-based Study in India
by: Prachee Sathe, et al.
Published: (2024-12-01)

Effectiveness of ceftazidime/avibactam as a continuous infusion in critically ill patients with OXA-48-producing Klebsiella pneumoniae infection
by: Ivan Šitum, et al.
Published: (2024-06-01)

In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis
by: Siquan Shen, et al.
Published: (2024-12-01)

Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction
by: Teerachat Saeheng, et al.
Published: (2024-11-01)

Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
by: Jingli Lu, et al.
Published: (2025-01-01)

Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran
by: Zhuan Yang, et al.
Published: (2024-11-01)

Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022
by: Xi Li, et al.
Published: (2024-12-01)

In vitro activity of ceftazidime-avibactam in combination with aztreonam against carbapenem resistant Enterobacterales isolated from intensive care units
by: Aya Bedawy, et al.
Published: (2024-11-01)

Pharmacogenetic and pharmacokinetic factors for dexmedetomidine-associated hemodynamic instability in pediatric patients
by: Yanping Guan, et al.
Published: (2025-01-01)

A Multicenter Retrospective Study on Real-World Outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan
by: Tsung Ying Zegma Yang, et al.
Published: (2024-12-01)

Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study
by: Thamer A. Almangour, et al.
Published: (2025-01-01)

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected in Turkey and the Middle East: ATLAS Global Surveillance Program 2018-2022
by: Meredith Hackel, et al.
Published: (2024-12-01)

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
by: Sunali, et al.
Published: (2025-01-01)

Predicting Pharmacokinetics of Active Constituents in <i>Spatholobi caulis</i> by Using Physiologically Based Pharmacokinetic Models
by: Xiaoyan Liu, et al.
Published: (2024-12-01)

Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony‐Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell Harvesting
by: Xu Jiang, et al.
Published: (2025-01-01)

Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy
by: Jim Abi Frem, et al.
Published: (2024-12-01)

Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility
by: Hana Farizah Zamri, et al.
Published: (2025-06-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Prediction of vancomycin plasma concentration in elderly patients based on multi-algorithm mining combined with population pharmacokinetics
by: Pan Ma, et al.
Published: (2024-11-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance
by: Tetsushu Onita, et al.
Published: (2025-01-01)

An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction
by: Ryutaro Iwama, et al.
Published: (2024-12-01)

Incidence of excess oxygen use in critically ill children and its impact on clinical outcomes: A single-center, retrospective study from Pakistan
by: Rubab Naz, et al.
Published: (2024-12-01)